Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Revenue (2016 - 2025)

Ptc Therapeutics has reported Revenue over the past 14 years, most recently at $164.7 million for Q4 2025.

  • Quarterly results put Revenue at $164.7 million for Q4 2025, down 22.75% from a year ago — trailing twelve months through Dec 2025 was $1.7 billion (up 179.1% YoY), and the annual figure for FY2025 was $1.7 billion, up 114.51%.
  • Revenue for Q4 2025 was $164.7 million at Ptc Therapeutics, down from $211.0 million in the prior quarter.
  • Over the last five years, Revenue for PTCT hit a ceiling of $1.2 billion in Q1 2025 and a floor of $116.7 million in Q2 2021.
  • Median Revenue over the past 5 years was $196.6 million (2023), compared with a mean of $238.2 million.
  • Biggest five-year swings in Revenue: plummeted 30.58% in 2024 and later surged 459.73% in 2025.
  • Ptc Therapeutics' Revenue stood at $165.2 million in 2021, then increased by 1.32% to $167.4 million in 2022, then skyrocketed by 83.41% to $307.1 million in 2023, then crashed by 30.58% to $213.2 million in 2024, then fell by 22.75% to $164.7 million in 2025.
  • The last three reported values for Revenue were $164.7 million (Q4 2025), $211.0 million (Q3 2025), and $178.9 million (Q2 2025) per Business Quant data.